To study whether the status of PTEN and/or Akt signaling affects the sensitivity of TMZ, we first analyzed the publicly available dataset in the Genomics of Drug Sensitivity in Cancer (GDSC) and The Cancer Genome Atlas Program (TCGA-GB) where GB samples were classified into two groups according to status of PTEN: wild type (n = 16 in GDSC-GB and n = 102 in TCGA-GB) and mutant (n = 17 in GDSC-GB and n = 47 in TCGA-GB). The gene discussed is AKT1; the disease is cancer.